Teprotumumab is effective in reducing proptosis in people with thyroid eye disease more than 2 years after treatment, and initial nonresponders to teprotumumab may benefit from a second series of infusions, according to a speaker.
“Responding to initial teprotumumab (Tepezza, Horizon Therapeutics) therapy may benefit during long-term follow-up,” George J. Kahaly, MD, PhD, a professor of medicine, endocrinology and metabolism at Johannes Gutenberg University Medical Center in Mainz, Germany, said during a presentation at the American Thyroid Association annual meeting. “Though